Open Briefing June 2018
A clinical-stage oncology drug company developing a disruptive technology for the treatment of solid cancers by radiotherapy and chemotherapy
Unique dual-acting anti-cancer drug
NOX66 Idronoxil (lipophilic form)
- inhibits DNA repair
inhibits PARP-1, topoisomerases 1 and 2
- promotes anti-tumour immunity
increases NK (natural killer) cell activity
To view Presentation please download PDF attached:
Download this document
